Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Non-canonical Small GTPase RBJ Promotes NSCLC Progression Through the Canonical MEK/ERK Signaling Pathway

Author(s): Yujin Wang, Xiaoyan Shen, Qingwen Wang, Zixin Guo, Liwen Hu, Zhe Dong* and Weidong Hu*

Volume 28, Issue 42, 2022

Published on: 28 November, 2022

Page: [3446 - 3455] Pages: 10

DOI: 10.2174/1381612829666221117124048

Price: $65

conference banner
Abstract

Background: Although the majority of members belonging to the small GTPase Ras superfamily have been studied in several malignancies, the function of RBJ has remained unclear, particularly in non-small cell lung cancer (NSCLC).

Objective: The research aims to determine the function of RBJ in NSCLC.

Methods: The levels of RBJ protein in tumor tissue and para-carcinoma normal tissue were ascertained via immunohistochemistry (IHC). The growth, migration, and invasion of NSCLC cells were assessed by 5- ethynyl-2-deoxyuridine (EdU) assay, colony formation, cell counting kit-8 (CCK8), transwell and wound healing assays. Furthermore, a nude mouse xenograft model was established to study the function of RBJ in tumorigenesis in vivo.

Results: The IHC analysis revealed that the protein levels of RBJ were notably increased in tumor tissue and positively associated with the clinical stage. In addition, the knockdown of RBJ restrained the growth, invasion, and migration of NSCLC cell lines by inhibiting the epithelial-mesenchymal transition (EMT) through the MEK/ERK signaling pathway. Accordingly, opposite results were observed when RBJ was overexpressed. In addition, the overexpression of RBJ accelerated tumor formation by A549 cells in nude mice.

Conclusion: RBJ promoted cancer progression in NSCLC by activating EMT via the MEK/ERK signaling. Thus, RBJ could be used as a potential therapeutic against NSCLC.

« Previous Next »
[1]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24(28): 4539-44.
[http://dx.doi.org/10.1200/JCO.2005.04.4859] [PMID: 17008692]
[3]
Zappa C, Mousa SA. Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res 2016; 5(3): 288-300.
[http://dx.doi.org/10.21037/tlcr.2016.06.07] [PMID: 27413711]
[4]
Hu W, Liu Y, Zhou W, Si L, Ren L. CXCL16 and CXCR6 are coexpressed in human lung cancer in vivo and mediate the invasion of lung cancer cell lines in vitro. PLoS One 2014; 9(6): e99056.
[http://dx.doi.org/10.1371/journal.pone.0099056] [PMID: 24897301]
[5]
Shen XY, Liu XP, Song CK, Wang YJ, Li S, Hu WD. Genome-wide analysis reveals alcohol dehydrogenase 1C and secreted phosphoprotein 1 for prognostic biomarkers in lung adenocarcinoma. J Cell Physiol 2019; 234(12): 22311-20.
[http://dx.doi.org/10.1002/jcp.28797] [PMID: 31074035]
[6]
Goitre L, Trapani E, Trabalzini L, Retta SF. The Ras superfamily of small GTPases: the unlocked secrets. Methods Mol Biol 2014; 1120: 1-18.
[http://dx.doi.org/10.1007/978-1-62703-791-4_1] [PMID: 24470015]
[7]
Nepomuceno-Silva JL, de Melo LDB, Mendonça SM, Paixão JC, Lopes UG. RJLs: A new family of Ras-related GTP-binding proteins. Gene 2004; 327(2): 221-32.
[http://dx.doi.org/10.1016/j.gene.2003.11.010] [PMID: 14980719]
[8]
Gao Z, Xing K, Zhang C, et al. Crystal structure and function of Rbj: A constitutively GTP-bound small G protein with an extra DnaJ domain. Protein Cell 2019; 10(10): 760-3.
[http://dx.doi.org/10.1007/s13238-019-0622-3] [PMID: 30945136]
[9]
Wen W, Cho YS, Zheng W, et al. Meta-analysis identifies common variants associated with body mass index in east Asians. Nat Genet 2012; 44(3): 307-11.
[http://dx.doi.org/10.1038/ng.1087] [PMID: 22344219]
[10]
Cherian PT, Al-Khairi I, Sriraman D, et al. Increased circulation and adipose tissue levels of DNAJC27/RBJ in obesity and type 2- diabetes. Front Endocrinol 2018; 9: 423.
[http://dx.doi.org/10.3389/fendo.2018.00423] [PMID: 30131766]
[11]
Chen T, Yang M, Yu Z, et al. Small GTPase RBJ mediates nuclear entrapment of MEK1/MEK2 in tumor progression. Cancer Cell 2014; 25(5): 682-96.
[http://dx.doi.org/10.1016/j.ccr.2014.03.009] [PMID: 24746703]
[12]
Ke C, Ren Y, Lv L, Hu W, Zhou W. Association between CXCL16/CXCR6 expression and the clinicopathological features of patients with non-small cell lung cancer. Oncol Lett 2017; 13(6): 4661-8.
[http://dx.doi.org/10.3892/ol.2017.6088] [PMID: 28599467]
[13]
Hu W, Zhen X, Xiong B, Wang B, Zhang W, Zhou W. CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells. Cancer Sci 2008; 99(7): 1362-9.
[http://dx.doi.org/10.1111/j.1349-7006.2008.00833.x] [PMID: 18452560]
[14]
Liu Q, Zhu H, Zhang C, Chen T, Cao X. Small GTPase RBJ promotes cancer progression by mobilizing MDSCs via IL-6. OncoImmunology 2017; 6(1): e1245265.
[http://dx.doi.org/10.1080/2162402X.2016.1245265] [PMID: 28197363]
[15]
Zhao Y, Adjei AA. The clinical development of MEK inhibitors. Nat Rev Clin Oncol 2014; 11(7): 385-400.
[http://dx.doi.org/10.1038/nrclinonc.2014.83] [PMID: 24840079]
[16]
Grimaldi AM, Simeone E, Festino L, Vanella V, Strudel M, Ascierto PA. MEK inhibitors in the treatment of metastatic melanoma and solid tumors. Am J Clin Dermatol 2017; 18(6): 745-54.
[http://dx.doi.org/10.1007/s40257-017-0292-y] [PMID: 28537004]
[17]
Duhamel S, Hébert J, Gaboury L, et al. Sef downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation. Cancer Res 2012; 72(3): 626-35.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-2126] [PMID: 22298595]
[18]
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417(6892): 949-54.
[http://dx.doi.org/10.1038/nature00766] [PMID: 12068308]
[19]
Slebos RJC, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323(9): 561-5.
[http://dx.doi.org/10.1056/NEJM199008303230902] [PMID: 2199829]
[20]
Zhao N, Wilkerson MD, Shah U, et al. Alterations of LKB1 and KRAS and risk of brain metastasis: Comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. Lung Cancer 2014; 86(2): 255-61.
[http://dx.doi.org/10.1016/j.lungcan.2014.08.013] [PMID: 25224251]
[21]
Kim C, Giaccone G. MEK inhibitors under development for treatment of non-small-cell lung cancer. Expert Opin Investig Drugs 2018; 27(1): 17-30.
[http://dx.doi.org/10.1080/13543784.2018.1415324] [PMID: 29216787]
[22]
Hay ED. An overview of epithelio-mesenchymal transformation. Cells Tissues Organs 1995; 154(1): 8-20.
[http://dx.doi.org/10.1159/000147748] [PMID: 8714286]
[23]
Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 2014; 16(6): 488-94.
[http://dx.doi.org/10.1038/ncb2976] [PMID: 24875735]
[24]
Fischer KR, Durrans A, Lee S, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015; 527(7579): 472-6.
[http://dx.doi.org/10.1038/nature15748] [PMID: 26560033]
[25]
Zheng X, Carstens JL, Kim J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015; 527(7579): 525-30.
[http://dx.doi.org/10.1038/nature16064] [PMID: 26560028]
[26]
Wang Y, Ngo VN, Marani M, et al. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 2010; 29(33): 4658-70.
[http://dx.doi.org/10.1038/onc.2010.218] [PMID: 20562906]
[27]
Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal 2014; 7(344): re8.
[http://dx.doi.org/10.1126/scisignal.2005189] [PMID: 25249658]
[28]
Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15(3): 178-96.
[http://dx.doi.org/10.1038/nrm3758] [PMID: 24556840]
[29]
Degirmenci U, Wang M, Hu J. Targeting aberrant RAS/RAF/ MEK/ERK signaling for cancer therapy. Cells 2020; 9(1): 198.
[http://dx.doi.org/10.3390/cells9010198] [PMID: 31941155]
[30]
Elias M, Archibald JM. The RJL family of small GTPases is an ancient eukaryotic invention probably functionally associated with the flagellar apparatus. Gene 2009; 442(1-2): 63-72.
[http://dx.doi.org/10.1016/j.gene.2009.04.011] [PMID: 19393304]
[31]
Walsh P, Bursać D, Law YC, Cyr D, Lithgow T. The J‐protein family: Modulating protein assembly, disassembly and translocation. EMBO Rep 2004; 5(6): 567-71.
[http://dx.doi.org/10.1038/sj.embor.7400172] [PMID: 15170475]
[32]
Song J, Takeda M, Morimoto RI. Bag1–Hsp70 mediates a physiological stress signalling pathway that regulates Raf-1/ERK and cell growth. Nat Cell Biol 2001; 3(3): 276-82.
[http://dx.doi.org/10.1038/35060068] [PMID: 11231577]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy